en.Wedoany.com Report on Mar 26th, Thermo Fisher Scientific and SHL Medical announced a strategic collaboration, while expanding the sterile fill-finish and autoinjector assembly capabilities at its facility in Ridgefield, New Jersey, USA, to advance integrated drug-device manufacturing. These initiatives collectively build a U.S.-based integrated service encompassing sterile drug-device manufacturing, device assembly, and commercial packaging for drug-device combination products.
The demand for patient-centric self-injection therapies is growing across multiple therapeutic areas, including autoimmune and chronic diseases. In response to this demand, Thermo Fisher is expanding fill-finish for pre-filled syringes and device assembly in Ridgefield. Concurrently, the collaboration with SHL Medical enables the integration of SHL Medical's Molly® autoinjector platform with Thermo Fisher's sterile drug-device manufacturing network, forming an end-to-end solution from drug product to finished device.
Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 as part of its efforts to strengthen its U.S. manufacturing footprint. The site is being developed into a North American integrated center for sterile fill-finish, final autoinjector assembly, and packaging, adding domestic capacity to support customer supply chains. Michelle Logan, Vice President of Thermo Fisher's North America Pharma - Sterile division, stated: "The collaboration with SHL Medical and our expansion in Ridgefield are important steps in helping our customers meet growing demand. By fully integrating fill-finish with device assembly, we can streamline supply chains, accelerate timelines, and ultimately support our customers in delivering critical therapies to patients more efficiently."
Under this strategic, non-exclusive collaboration, Thermo Fisher and SHL Medical will provide integrated support at the Ridgefield site for SHL Medical's Molly® autoinjector platform, including final device assembly, packaging, and distribution. The collaboration aims to simplify development and manufacturing processes for pharmaceutical and biotechnology customers, supporting a streamlined path from drug product manufacturing to commercialization. Markus Puusepp, Chief Growth Officer at SHL Medical, said: "The collaboration with Thermo Fisher is a significant milestone for SHL Medical and the customers we serve together. By combining SHL Medical's proven Molly® autoinjector platform and global device expertise with Thermo Fisher's leading sterile fill-finish and commercial manufacturing capabilities, we are creating a powerful integrated solution. This facility in Ridgefield underscores our shared commitment to supporting the growing demand for high-quality, patient-centric combination products and accelerating time-to-market for innovative therapies globally."
The addition of autoinjector capabilities in Ridgefield complements Thermo Fisher's global network, including facilities in Allentown, Pennsylvania; Horsham, UK; and planned capacity in Greenville, North Carolina, creating a scalable platform across development and commercial stages. Continued investment in its sterile network, including expansions in Greenville, North Carolina; Ferentino, Italy; and the Asia-Pacific region, further strengthens the company's ability to support customers with integrated, global manufacturing solutions, advancing integrated drug-device manufacturing.
